U.S. FDA Approves Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require TransfusionsBusiness Wire • 08/29/23
Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)Business Wire • 08/28/23
Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle PlatformPRNewsWire • 08/28/23
Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023Business Wire • 08/25/23
Bristol-Myers Squibb: Top Defensive Pick During Recessions With A Value PropositionSeeking Alpha • 08/24/23
Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity CommitmentsBusiness Wire • 08/23/23
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC MelanomaBusiness Wire • 08/22/23
Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023Business Wire • 08/21/23
Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerBusiness Wire • 08/16/23
Bristol Myers Squibb stock extends bounce after announced $4 billion accelerated buyback agreementsMarket Watch • 08/10/23
Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity EffortsBusiness Wire • 08/10/23
Bristol Myers Squibb Enters Into $4 Billion Aggregate Accelerated Share Repurchase AgreementsBusiness Wire • 08/10/23
Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque PsoriasisBusiness Wire • 08/08/23